182 related articles for article (PubMed ID: 18596117)
1. Consistent control of mineral and bone disorder in incident hemodialysis patients.
Danese MD; Belozeroff V; Smirnakis K; Rothman KJ
Clin J Am Soc Nephrol; 2008 Sep; 3(5):1423-9. PubMed ID: 18596117
[TBL] [Abstract][Full Text] [Related]
2. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345
[TBL] [Abstract][Full Text] [Related]
3. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
[TBL] [Abstract][Full Text] [Related]
4. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
[TBL] [Abstract][Full Text] [Related]
5. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.
Block GA; Kilpatrick RD; Lowe KA; Wang W; Danese MD
Clin J Am Soc Nephrol; 2013 Dec; 8(12):2132-40. PubMed ID: 24052218
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
7. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study.
Wald R; Sarnak MJ; Tighiouart H; Cheung AK; Levey AS; Eknoyan G; Miskulin DC
Am J Kidney Dis; 2008 Sep; 52(3):531-40. PubMed ID: 18657891
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
Palmer SC; Hayen A; Macaskill P; Pellegrini F; Craig JC; Elder GJ; Strippoli GF
JAMA; 2011 Mar; 305(11):1119-27. PubMed ID: 21406649
[TBL] [Abstract][Full Text] [Related]
9. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
[TBL] [Abstract][Full Text] [Related]
10. [Management of mineral and bone disease caused by chronic renal disease: what recommendations have contributed].
Houillier P;
Nephrol Ther; 2008 Sep; 4 Spec No 1():2-8, 15-9. PubMed ID: 19031626
[No Abstract] [Full Text] [Related]
11. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.
Kalantar-Zadeh K; Kuwae N; Regidor DL; Kovesdy CP; Kilpatrick RD; Shinaberger CS; McAllister CJ; Budoff MJ; Salusky IB; Kopple JD
Kidney Int; 2006 Aug; 70(4):771-80. PubMed ID: 16820797
[TBL] [Abstract][Full Text] [Related]
12. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
Cozzolino M; Messa P; Brancaccio D; Cannella G; Bolasco P; Di Luca M; Costanzo AM; Paparatti Ud; Festa V; Gualberti G; Mazzaferro S;
Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
[TBL] [Abstract][Full Text] [Related]
13. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.
Taniguchi M; Fukagawa M; Fujii N; Hamano T; Shoji T; Yokoyama K; Nakai S; Shigematsu T; Iseki K; Tsubakihara Y;
Ther Apher Dial; 2013 Apr; 17(2):221-8. PubMed ID: 23551679
[TBL] [Abstract][Full Text] [Related]
14. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
[TBL] [Abstract][Full Text] [Related]
15. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
16. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
Slinin Y; Foley RN; Collins AJ
J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
[TBL] [Abstract][Full Text] [Related]
17. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines.
Komaba H; Igaki N; Takashima M; Goto S; Yokota K; Komada H; Takemoto T; Kohno M; Kadoguchi H; Hirosue Y; Goto T
Ther Apher Dial; 2008 Feb; 12(1):42-8. PubMed ID: 18257811
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
19. Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines.
Liu Y; Lee WC; Cheng BC; Li LC; Lee CH; Chang WX; Chen JB
Biomed Res Int; 2016; 2016():1523124. PubMed ID: 28003998
[No Abstract] [Full Text] [Related]
20. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
